• Sofinnova Partners backed Myricx Bio, a UK-origin oncology company developing antibody-drug conjugates using an NMT inhibitor payload platform.
• Sofinnova Partners, Brandon Capital co-led a seed financing in 2019 to test whether the lead molecule could achieve a viable therapeutic index.
• Myricx later raised a GBP 90 million Series A in 2024, with Sofinnova continuing support while remaining the largest investor.
• The financing supported a pivot from a small-molecule program to an ADC payload platform targeting B7-H3 and HER2 in solid tumors.
• Myricx agreed to be acquired by Novartis for up to USD 1.5 billion, including USD 1.1 billion upfront.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sofinnova Partners SAS published the original content used to generate this news brief on July 08, 2026, and is solely responsible for the information contained therein.